

Resource Summary Report

Generated by [NIF](#) on Jul 31, 2026

Rabbit Anti-Met, phospho (Tyr1234 / Tyr1235) Monoclonal Antibody, Unconjugated, Clone D26

RRID:AB_2143884

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3077, RRID:AB_2143884

Antibody Information

URL: http://antibodyregistry.org/AB_2143884

Proper Citation: Cell Signaling Technology Cat# 3077, RRID:AB_2143884

Target Antigen: Met

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IHC-F, IF-IC, F. Consolidation on 11/2018: AB_10328091, AB_10329175, AB_2143884, AB_2235289, AB_2315156.

Antibody Name: Rabbit Anti-Met, phospho (Tyr1234 / Tyr1235) Monoclonal Antibody, Unconjugated, Clone D26

Description: This monoclonal targets Met

Target Organism: rat, mouse, human

Antibody ID: AB_2143884

Vendor: Cell Signaling Technology

Catalog Number: 3077

Record Creation Time: 20250820T044142+0000

Record Last Update: 20250820T194111+0000

Ratings and Alerts

No rating or validation information has been found for Rabbit Anti-Met, phospho (Tyr1234 / Tyr1235) Monoclonal Antibody, Unconjugated, Clone D26.

No alerts have been found for Rabbit Anti-Met, phospho (Tyr1234 / Tyr1235) Monoclonal Antibody, Unconjugated, Clone D26.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 51 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Lamichhane A, et al. (2025) Targeting CAFs-Mediated Stromal Signaling in a Patient-Derived Organotypic Colorectal Tumor Model. *Molecular cancer therapeutics*, 24(8), 1265.

Kang J, et al. (2025) Multi-layer stratified oncology platform utilizing transcriptomics, prostate cancer organoids, and modeling of drug response. *Journal of experimental & clinical cancer research : CR*, 44(1), 290.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. *Cell chemical biology*, 32(6), 839.

Cui Y, et al. (2025) MET receptor tyrosine kinase promotes the generation of functional synapses in adult cortical circuits. *Neural regeneration research*, 20(5), 1431.

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. *Cell reports. Medicine*, 6(2), 101929.

Maurya SK, et al. (2025) Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET/CD44v6. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 921.

Schimmel MF, et al. (2025) Development of a cyst-targeted therapy for polycystic kidney disease using an antagonistic dimeric IgA monoclonal antibody against cMET. *Cell reports. Medicine*, 6(9), 102335.

Poliakov?? Turan M, et al. (2024) E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. *Cancer research communications*, 4(7), 1863.

Seenan V, et al. (2024) Ovulation provides excessive coagulation and hepatocyte growth factor signals to cause postoperative intraabdominal adhesions. *iScience*, 27(6), 109788.

Deng Y, et al. (2024) LIFR regulates cholesterol-driven bidirectional hepatocyte-neutrophil cross-talk to promote liver regeneration. *Nature metabolism*, 6(9), 1756.

Roper N, et al. (2024) Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer. *Cancer research communications*, 4(2), 337.

Rojas-Chaverra NM, et al. (2024) A cyclic peptide-grafted Fc with hepatocyte growth factor functionality ameliorates hepatic fibrosis in a non-alcoholic steatohepatitis mouse model. *iScience*, 27(8), 110426.

Wang J, et al. (2024) Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. *Cell reports. Medicine*, 5(2), 101388.

Ye F, et al. (2024) Endocytic activation and exosomal secretion of matriptase stimulate the second wave of EGF signaling to promote skin and breast cancer invasion. *Cell reports*, 43(4), 114002.

Zhou CQ, et al. (2024) Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor-Tolerant Cells in NSCLC Patient-Derived Xenografts. *Cancer research communications*, 4(9), 2308.

Gurska LM, et al. (2023) Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(5), 943.

Choi YR, et al. (2023) Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer. *British journal of cancer*.

Kha M, et al. (2023) The injury-induced transcription factor SOX9 alters the expression of LBR, HMGA2, and HIPK3 in the human kidney. *American journal of physiology. Renal physiology*, 324(1), F75.

Zuo Q, et al. (2023) Plexin-B3 expression stimulates MET signaling, breast cancer stem cell specification, and lung metastasis. *Cell reports*, 42(3), 112164.

Miyake K, et al. (2023) A cancer-associated METTL14 mutation induces aberrant m6A modification, affecting tumor growth. *Cell reports*, 42(7), 112688.